Zabalafin’s All-In-One Assault On Inflammation, Infection, Dryness, and Itch
Atopic dermatitis has long been driven by a vicious circle—staph overgrowth, immune flare-ups, parched skin, and relentless itch that feed one another. Now, an expert panel’s consensus and a first-in-class phase 2a trial suggest a single topical hydrogel may finally break the cycle. Zabalafin not only soothes inflammation and curbs Staphylococcus aureus colonization but also restores moisture and quells pruritus, all with minimal side effects in patients with mild to moderate AD.
For dermatologists eager to move beyond one-dimensional treatments, this multi-targeted strategy offers a fresh blueprint for sustained disease control. Read the full article to see how recognizing the AD continuum and deploying zabalafin could reshape your treatment landscape—and give your patients lasting relief.
J Drugs Dermatol. 2025;24(9): doi:10.36849/JDD.9230
Blog write-up assisted by AI
